Birdshot chorioretinopathy (BSCR) is extremely rare. It accounts for roughly 1% to 3% of all uveitis cases seen at specialized eye centers, making it one of the least common forms of inflammatory eye disease. Because uveitis itself affects only a small fraction of the population, BSCR is vanishingly uncommon in the general population, with estimated prevalence figures in the range of 1 to 6 per million people in Northern Europe and North America.
Who Gets Birdshot Chorioretinopathy
BSCR overwhelmingly affects white individuals of Northern European descent. Cases in Latino-Hispanic, African-American, Japanese, and South Asian populations are limited to isolated case reports. This strong ethnic skew is one of the defining features of the disease and is directly tied to a genetic marker called HLA-A29, which is far more common in people of European ancestry.
The mean age at diagnosis is 53, though cases have been reported in patients as young as 15 and as old as 79. Some studies show a slight majority of female patients (around 54%), but this likely reflects women’s longer life expectancy rather than a true difference in risk. For practical purposes, BSCR has no meaningful gender predominance.
The HLA-A29 Connection
About 96% of people diagnosed with BSCR carry the HLA-A29 gene variant, one of the strongest associations between a genetic marker and any disease. HLA-A29 is part of the immune system’s machinery for identifying threats, and something about this variant appears to trigger an autoimmune attack on the choroid, the blood vessel layer at the back of the eye. The exact mechanism remains unclear.
Carrying HLA-A29 does not mean you will develop BSCR. Roughly 7% of the general white population has this gene variant, yet only a tiny fraction ever develops the disease. Other genetic or environmental triggers are almost certainly involved, but none have been definitively identified.
What BSCR Feels Like
The earliest symptoms are typically floaters and blurred vision, usually in both eyes. Unlike many forms of eye inflammation, BSCR rarely causes pain or redness, which can delay diagnosis. Over time, symptoms can expand to include night blindness, difficulty distinguishing colors, loss of peripheral vision, and sensitivity to bright lights or glare.
Some patients describe more unusual visual disturbances: shimmering or hazy vision (like looking through dirty glass), flickering lights, distorted shapes, or a spinning pinwheel effect when they close their eyes. These symptoms tend to develop gradually, which is another reason BSCR often goes unrecognized for months or even years before a correct diagnosis.
How It’s Diagnosed
Diagnosis relies on a combination of clinical findings and, in many cases, HLA-A29 testing. The hallmark feature is a pattern of cream-colored or yellow-orange oval spots scattered across the back of the eye, the “birdshot” lesions that give the disease its name. These spots appear in both eyes.
The international classification criteria require this characteristic pattern of spots along with minimal inflammation in the front chamber of the eye and no more than moderate haziness in the vitreous (the gel filling the eye). A positive HLA-A29 test can support the diagnosis even when the spots are subtle. Before confirming BSCR, doctors must also rule out syphilis, sarcoidosis, and intraocular lymphoma, all of which can mimic the appearance of birdshot lesions.
Treatment and What to Expect
BSCR is a chronic condition that requires long-term treatment. Steroid medications are typically the first step because they suppress inflammation quickly, but steroids alone are considered ineffective for sustained control. Most patients need a second-line immunosuppressive drug to keep the disease in check while reducing steroid doses and their side effects.
The most commonly used long-term medications work by dampening the overactive immune response that drives the disease. In cases that don’t respond to these standard options, newer biologic therapies have shown effectiveness. Treatment is usually ongoing for years, sometimes indefinitely, with regular monitoring to catch flare-ups early.
The good news is that visual acuity generally improves with treatment. In studies tracking patients over time, most maintained functional vision. However, some patients do experience progressive vision loss despite therapy, and complications like swelling in the central retina can require additional interventions such as injections directly into the eye.
Long-Term Vision Outlook
BSCR progresses slowly, and its impact on vision varies widely. In one long-term follow-up study, 17% of patients eventually became legally blind in both eyes. That means the large majority retained useful vision over many years, but the risk of significant impairment is real and underscores why consistent treatment and monitoring matter.
The greatest threats to long-term vision are chronic swelling in the macula (the part of the retina responsible for sharp central vision), gradual thinning of the retina, and damage to the optic nerve. Night vision and color perception tend to be affected earlier and more severely than daytime visual sharpness, which can make the disease feel deceptively mild in its early stages. By the time central vision noticeably declines, substantial damage to the retina may already have occurred, which is why specialists push for early, aggressive treatment even when symptoms seem manageable.